Ascentage Pharma Group International (AAPG) Long-Term Deferred Tax (2023 - 2026)

Ascentage Pharma Group International's Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $4.5 million for Q4 2025.

• In Q4 2025, Long-Term Deferred Tax fell 26.84% year-over-year to $4.5 million; the TTM figure through Dec 2025 stood at $4.5 million (down 26.84% YoY), while the FY2025 annual figure was $4.6 million, down 24.59% from the prior year.
• Long-Term Deferred Tax for Q4 2025 stood at $4.5 million, down from $4.7 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $8.4 million in Q4 2022, with the low at $2.3 million in Q4 2023.
• The 4-year median for Long-Term Deferred Tax is $4.7 million (2025), against an average of $5.2 million.
• The sharpest annual moves came in 2023 and 2024: Long-Term Deferred Tax slumped 72.83% in 2023, then jumped 170.34% in 2024.
• Ascentage Pharma Group International's Long-Term Deferred Tax stood at $8.4 million in 2022, then plunged by 72.83% to $2.3 million in 2023, then soared by 170.34% to $6.2 million in 2024, then fell by 26.84% to $4.5 million in 2025.
• Business Quant data shows AAPG's Long-Term Deferred Tax at $4.5 million in Q4 2025, $4.7 million in Q2 2025, and $6.2 million in Q4 2024.